Scientific context only. Not medical advice, not a recommendation to use.
At a glance
Synthetic hexapeptide of the GH secretagogue family. Approved in Japan as GHRP Kaken as a diagnostic test for GH deficiency. Not available as a medicine outside Japan.
Researched for
Diagnosis of growth-hormone deficiencyAcute GH provocation
Official status
US: Unapproved
No FDA approval. Sale as a 'research chemical' is not legally covered; veterinary applications are also not authorised.
GHRP-2 binds with high affinity to the GH secretagogue receptor (GHSR-1a) in the pituitary and hypothalamus. Activation leads to rapid release of pulsatile growth hormone. Unlike GHRH, GHRP-2 acts via a separate pathway and can be combined synergistically with GHRH to elicit maximal GH responses in provocation tests.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
3 observations · 2 tiers
Human trial
2
Animal model
1
03
What the studies show
Human trial
Mensch
Bowers CY. et al. 1992
Robust acute GH rise after single intravenous or subcutaneous administration documented in healthy volunteers and in GH-deficient patients
What does NOT follow: Diagnostic, not therapeutic endpoint; chronic administration has not been approved for GH replacement therapy.
Human trial
Mensch
Discrimination between GH deficiency and constitutional growth delay demonstrated in a Japanese paediatric study
What does NOT follow: Specific application context of the Japanese approval.
Animal model
Ratte / Maus
Stimulation of ghrelin-like appetite pathways described in animal models
What does NOT follow: Clinical relevance in humans not established.
05
Pharmacokinetics
Theoretical concentration curve at a half-life of 0.5 h. Pure pharmacokinetic model — not a dosing recommendation.
Which routes of administration the available studies describe — neutral reporting, not a usage guide.
Intravenous
In the Japanese approval setup used as an IV bolus for GH provocation.
Subcutaneous
In research settings also administered subcutaneously.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Human trial
Acute nausea / dizziness
Reports from diagnostic studies; mostly brief and self-limiting.
gelegentlich nach IV-Gabe
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
08
Risks & hygiene aspects in the literature
What regulatory and scientific literature reports on risks, sterility and identity in non-pharmaceutical sources — descriptive, not a hygiene guide.
WADA status
GHRP-2 is on the WADA prohibited list under S2 as a GH secretagogue.
10
Anecdotal observations
Weakest evidence tier — not supported by studies
Reading note. This section gathers popular claims from communities and forums. They are explicitly marked as weakest-tier evidence. Unblinded self-reports are particularly prone to placebo, recall and confirmation biases.
Why no amounts or protocols are listed here. We deliberately show only WHAT communities report — not in what amount or how it is used. Anecdotal "doses" or "biohacker protocols" are neither verified nor standardised nor safe; publishing them would be a usage guide, which we do not provide on principle. Specific amounts belong in a conversation with a doctor, not in a forum.
Forums describe the combination of GHRP-2 with Mod-GRF/CJC-1295 as a 'standard stack'.
widespread in English-language bodybuilding forums
Not supported by studies: Combination use outside the approved indication (Japan diagnostics) is not supported by any controlled human trials for endpoints such as body composition or muscle building.
11
Legal status by country
Country
Status
Note
Checked
JP
Prescription
Approved in Japan as GHRP Kaken (intravenous diagnostic test for GH deficiency).
2026-05-22
United States
Unapproved
No FDA approval. Sale as a 'research chemical' is not legally covered; veterinary applications are also not authorised.
2026-05-22
Germany
Unapproved
No EMA approval. WADA-prohibited.
2026-05-22
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
1Enter the vial's substance amount (printed on the label).
2Enter how much solvent you add.
3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.